Business
New 5-FU/Capecitabine Safety & Treatment Test
New 5-FU/Capecitabine Safety & Treatment Test.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n \n\n \n23 August 2024\nEDX Medical Group plc · EDX\n AQSE: EDX\n(\"EDX Medical\" or the \"Company\")\n \n\nDEVELOPMENT OF NEW 5-FU/Capecitabine\nsafety and treatment management test\n\n \nCAMBRIDGE, UK: EDX Medical Group plc (AQSE: EDX) (\"EDX Medical\" or the \"Company\"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has today announced a further important development in its cancer testing capability in collaboration with The University of Oxford.\n \nEDX Medical has entered into an exclusive agreement with Oxford University Innovation Ltd (OUI), the company which manages Oxford University's patent portfolio, to in-license new intellectual property developed by researchers at Oxford and Birmingham Universities through research funded by Cancer Research UK (CRUK).\n \nThis will enable EDX Medical to develop a much-improved test to determine safety and dose management for individual patients receiving 5-fluorouracil (5-FU), capecitabine and related chemotherapy medications. These drugs are widely used in the first-line treatment of colorectal cancer, breast cancer and cancers of the upper gastrointestinal tract but carry serious adverse side effects for certain individuals.\n \nThe new test from EDX Medical will incorporate the detection of a number of proprietary genes associated with severe adverse reactions in addition to the four dihydropyrimidine dehydrogenase (DPYD) genetic variants currently tested. The enlarged gene panel will provide a more accurate and complete prediction of dose-related clinical risks. The new test will be available exclusively from EDX Medical.\n \nThe Board of EDX Medical believes the new test has the potential to benefit millions of patients worldwide. More than 10 million people globally receive some form of chemotherapy annually and in England alon...